Abstract:Antidepressant drugs such as the serotonin (5-HT)/norepinephrine (NE) and dopamine (DA) reuptake inhibitors activate monoaminergic neurotransmission in various brain regions, such as the amygdala, the frontal cortex or the hippocampus. Although this property is well established, the post-synaptic mechanisms by which these pharmacological agents exert therapeutic activity in major depressive disorders (MDD) is not fully understood. Recent clinical and preclinical studies have indicated that the density and reactivity of glia and more particularly of astrocytes are reduced in MDD patients. These data along with the fact that astrocytes express monoaminergic transporters and receptors make these cells putative targets for antidepressant treatments. Accordingly, in vitro evidence has demonstrated that the application of various classes of antidepressant drugs on rodent primary astrocyte cultures elicits a wide spectrum of responses, from the rise in cytosolic calcium concentrations, as a marker of cellular activity, to the release of glucose metabolites, gliotransmitters and neurotrophic factors. Remarkably, antidepressant drugs also attenuate the release of inflammatory molecules from reactive astrocytes or microglia, suggesting that part of the beneficial effects in depressed patients or animal models of depression might result from the ability of antidepressants to regulate the synthesis and release of psychoactive substances acting on both pre- and post-synaptic neurons. Among the many long-term targets of antidepressant drugs, brainderived neurotrophic factor (BDNF) has been well studied because of the positive influence on adult hippocampal neurogenesis, synaptogenesis and the local serotonergic tone. This review will illustrate how the concept of the tripartite synapse, which is classically associated with different forms of plasticity involving glutamate, could be expanded to the monoaminergic systems to regulate antidepressant drug responses. The recent in vivo data supporting that hippocampal astrocytes act in concert with neurons to release BDNF under pharmacological conditions and thereby regulate different facets of anxiolytic-/antidepressant-like activities through neurogenesis-dependent and independent mechanisms will be emphasized.

Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications

Changes in Hippocampal Plasticity in Depression and Therapeutic Approaches Influencing These Changes

Neuroplasticity: Pathophysiology and Role in Major Depressive Disorder

Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression

5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology

N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity

Synaptic plasticity in depression: molecular, cellular and functional correlates

Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review)

Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model

From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder

Pathogenesis of depression: Insights from human and rodent studies

Neural Plasticity and Depression Treatment

Neuroplasticity and the Biological Role of Brain Derived Neurotrophic Factor in the Pathophysiology and Management of Depression

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity

Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments

Signaling pathways involved in antidepressant-induced cell proliferation and synaptic plasticity.

Targeting Gap Junctions: New Insights into the Treatment of Major Depressive Disorder